Investment
Features
FeesSafety
Academy
More
Pluang+

Profusa signs term sheet to acquire diagnostics firm and announces key management changes

Company Fundamentals
27 Jul 2026
GlobeNewsWire
View Source
Bullish
Profusa signs term sheet to acquire diagnostics firm and announces key management changes

Profusa, a digital health company, signed a non-binding term sheet to acquire a commercial-stage diagnostics company with estimated 2025 revenues of $111 million. The acquisition will create a public diagnostics firm with national CLIA-certified labs serving addiction, pain management, and behavioral health providers. Profusa also appointed Jack Stover as Executive Chairman and CEO, with former CEO Ben Hwang becoming President. The deal includes issuing Profusa stock and preferred shares to the acquired company's shareholders, alongside a planned $7 million convertible note financing to support the transaction.

More News

Volkswagen recalls 208,000+ SUVs in US over steering bolt corrosion risk

Volkswagen recalls 208,000+ SUVs in US over steering bolt corrosion risk

Volkswagen Group of America is recalling over 208,000 SUVs in the US, including certain 2018 Tiguan, 2018-2019 Atlas, and 2019-2021 Audi Q3 models, due to a steering rack mounting bolt that can corrode and break. This defect could cause a loss of ste...

Market News
Bearish
4 hours ago
Prismo Metals maps a large alteration system at Silver King, indicating a deep porphyry copper target.

Prismo Metals maps a large alteration system at Silver King, indicating a deep porphyry copper target.

Prismo Metals completed its 2026 surface reconnaissance at the Silver King project in Arizona, revealing an alteration system over 2 km wide with classic porphyry copper zoning. The findings include expanded potassic alteration, phyllic overprinting,...

Market News
Bullish
4 hours ago
Coiled Therapeutics enrolls patients for new softgel cancer drug trial to improve absorption and dosing.

Coiled Therapeutics enrolls patients for new softgel cancer drug trial to improve absorption and dosing.

Coiled Therapeutics has enrolled six patients into two dosing groups testing a reformulated version of its cancer drug AO-252, designed to better cross the brain and block the cancer-driving protein TACC3. The new lipid-based softgel aims to provide ...

Market News
Bullish
4 hours ago
Iofina targets record iodine output in 2026 as profits surge on higher production and margins

Iofina targets record iodine output in 2026 as profits surge on higher production and margins

Iofina PLC expects to produce a record volume of iodine in 2026, with output forecasted between 460 and 485 metric tonnes in the second half of the year. The company reported a sharp rise in profitability for the first half, with adjusted core earnin...

Company Fundamentals
Bullish
4 hours ago
Accsys expects higher adjusted EBITDA despite 6% revenue drop amid cautious market conditions.

Accsys expects higher adjusted EBITDA despite 6% revenue drop amid cautious market conditions.

Accsys Technologies Plc forecasts full-year adjusted EBITDA between €21 million and €23 million, surpassing last year's results despite a 6% revenue decline to €56.9 million in the first five months. Sales volumes dropped 11%, impacted by distributor...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App